Ziprasidone hydrochloride monohydrate

• CAT Number: I001496
• CAS Number: 138982-67-9
• Molecular Formula: C21H21ClN4OS • HCl [H2O]
• Molecular Weight: 467.40
• Purity: ≥95%
• Synonyms: 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one, monohydrochloride, monohydrate
• Target: Neuronal Signaling
• Solubility: DMSO:>10 mg/mL
• Storage: -20°C
• IUPAC Name: 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one;hydrate;hydrochloride
• InChI: InChI=1S/C21H21ClN4OS.ClH.H2O/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21;;/h1-4,11,13H,5-10,12H2,(H,23,27);1H;1H2
• InChIKey: ZCBZSCBNOOIHFP-UHFFFAOYSA-N
• SMILES: C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54.O.Cl

Ziprasidone hydrochloride monohydrate（Cat No.:I001496）is an atypical antipsychotic medication used to treat schizophrenia and bipolar disorder. It works by modulating the activity of various neurotransmitters in the brain, including serotonin, dopamine, and norepinephrine. By blocking specific receptors, it helps to alleviate symptoms such as hallucinations, delusions, and mood instability. Ziprasidone is often preferred due to its relatively low risk of metabolic side effects compared to other antipsychotics. It is available in both oral and injectable forms and is generally well-tolerated, though it may cause side effects like sedation, dizziness, or prolonged QT intervals.

Reference

[1]. Papakostas GI, Petersen TJ, Nierenberg AA, et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. The Journal of Clinical Psychiatry. 2004, 65(2):217-221.
[2]. Paul E. Keck, Marcio Versiani, Steven Potkin, et al. Ziprasidone in the Treatment of Acute Bipolar Mania: A Three-Week, Placebo-Controlled, Double-Blind, Randomized Trial. Am J Psychiatry 2003;160:741-748.
[3]. Glen L. Stimmel, Mary A. Gutierrez, Vivian Lee. Ziprasidone: An atypical antipsychotic drug for the treatment of schizophrenia. Clinical Therapeutics, 2002, 24(1):21-37.
[4]. Anne W Schmidt, Lorraine A Lebel, Harry R Howard Jr. et al. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. European Journal of Pharmacology. 2001,425(3):197-201.
[5]. Ziprasidone